PT - JOURNAL ARTICLE AU - Joshi, Keya AU - Rumpler, Eva AU - Kennedy-Shaffer, Lee AU - Bosan, Rafia AU - Lipsitch, Marc TI - Comparative performance of between-population allocation strategies for SARS-CoV-2 vaccines AID - 10.1101/2021.06.18.21259137 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.18.21259137 4099 - http://medrxiv.org/content/early/2021/06/21/2021.06.18.21259137.short 4100 - http://medrxiv.org/content/early/2021/06/21/2021.06.18.21259137.full AB - Vaccine allocation decisions during the ongoing COVID-19 pandemic have proven to be challenging due to competing ethical, practical, and political considerations. Complicating decision making, policy makers need to consider vaccine allocation strategies that balance needs both within and between populations. Due to limited vaccine stockpiles, vaccine doses should be allocated in locations where their impact will be maximized. Using a susceptible-exposed-infectious-recovered (SEIR) model we examine optimal SARS-CoV-2 vaccine allocation decisions across two populations considering the impact of population size, underlying immunity, continuous vaccine roll-out, and heterogeneous population risk structure. We find that in the context of an emerging pathogen, where many epidemiologic characteristics might not be known, equal vaccine allocation between populations performs optimally in most scenarios. In the specific case considering heterogeneous population risk structure, first targeting individuals at higher risk of transmission or death due to infection leads to equitable resource allocation across populations.Competing Interest StatementKeya Joshi, Eva Rumpler, Lee Kennedy-Shaffer and Rafia Bosan have no conflicts of interest to disclose. Marc Lipsitch reports consulting/honoraria from Bristol Myers Squibb, Sanofi Pasteur, Janssen, and Merck, as well as institutional funding from Pfizer. He has served as an unpaid advisor related to COVID-19 to Pfizer, One Day Sooner, Astra-Zeneca, Janssen, and COVAX (United Biomedical).Funding StatementER, LKS and ML were supported by the Morris-Singer Fund. This work was supported in part by Award Number U01CA261277 from the US National Cancer Institute of the National Institutes of Health. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the Morris-Singer Fund or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and code will be available on GitHub.